232 related articles for article (PubMed ID: 33504554)
21. Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma.
Hurkmans DP; Jensen C; Koolen SLW; Aerts J; Karsdal MA; Mathijssen RHJ; Willumsen N
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093157
[TBL] [Abstract][Full Text] [Related]
22. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
23. A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma.
Girault I; Adam J; Shen S; Roy S; Brard C; Faouzi S; Routier E; Lupu J; Warren S; Sorg K; Ong S; Morel P; Scoazec JY; Vagner S; Robert C
Clin Cancer Res; 2022 Feb; 28(3):518-525. PubMed ID: 34785583
[TBL] [Abstract][Full Text] [Related]
24. Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study.
Liu R; Yang F; Yin JY; Liu YZ; Zhang W; Zhou HH
Front Immunol; 2021; 12():685370. PubMed ID: 34220837
[TBL] [Abstract][Full Text] [Related]
25. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
Waninger JJ; Ma VT; Journey S; Skvarce J; Chopra Z; Tezel A; Bryant AK; Mayo C; Sun Y; Sankar K; Ramnath N; Lao C; Sussman JB; Fecher L; Alva A; Green MD
JAMA Netw Open; 2021 Mar; 4(3):e210980. PubMed ID: 33687443
[TBL] [Abstract][Full Text] [Related]
26. Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
Levine LS; Mahuron KM; Tsai KK; Wu C; Mattis DM; Pauli ML; Oglesby A; Lee JC; Spitzer MH; Krummel MF; Algazi AP; Rosenblum MD; Alvarado M; Daud AI
Ann Surg Oncol; 2020 Oct; 27(11):4122-4130. PubMed ID: 32488521
[TBL] [Abstract][Full Text] [Related]
27. A novel process for H&E, immunofluorescence, and imaging mass cytometry on a single slide with a concise analytics pipeline.
Marlin MC; Stephens T; Wright C; Smith M; Wright K; Guthridge JM
Cytometry A; 2023 Dec; 103(12):1010-1018. PubMed ID: 37724720
[TBL] [Abstract][Full Text] [Related]
28. The density and spatial tissue distribution of CD8
Massi D; Rulli E; Cossa M; Valeri B; Rodolfo M; Merelli B; De Logu F; Nassini R; Del Vecchio M; Di Guardo L; De Penni R; Guida M; Sileni VC; Di Giacomo AM; Tucci M; Occelli M; Portelli F; Vallacchi V; Consoli F; Quaglino P; Queirolo P; Baroni G; Carnevale-Schianca F; Cattaneo L; Minisini A; Palmieri G; Rivoltini L; Mandalà M;
J Immunother Cancer; 2019 Nov; 7(1):308. PubMed ID: 31730502
[TBL] [Abstract][Full Text] [Related]
29. Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma.
Yaseen Z; Gide TN; Conway JW; Potter AJ; Quek C; Hong AM; Long GV; Scolyer RA; Wilmott JS
Front Mol Biosci; 2022; 9():810858. PubMed ID: 35664673
[TBL] [Abstract][Full Text] [Related]
30. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
Pelekanou V; Villarroel-Espindola F; Schalper KA; Pusztai L; Rimm DL
Breast Cancer Res; 2018 Dec; 20(1):154. PubMed ID: 30558648
[TBL] [Abstract][Full Text] [Related]
31. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
32. A 40-Marker Panel for High Dimensional Characterization of Cancer Immune Microenvironments by Imaging Mass Cytometry.
Ijsselsteijn ME; van der Breggen R; Farina Sarasqueta A; Koning F; de Miranda NFCC
Front Immunol; 2019; 10():2534. PubMed ID: 31736961
[TBL] [Abstract][Full Text] [Related]
33. A 34-Marker Panel for Imaging Mass Cytometric Analysis of Human Snap-Frozen Tissue.
Guo N; van Unen V; Ijsselsteijn ME; Ouboter LF; van der Meulen AE; Chuva de Sousa Lopes SM; de Miranda NFCC; Koning F; Li N
Front Immunol; 2020; 11():1466. PubMed ID: 32765508
[TBL] [Abstract][Full Text] [Related]
34. Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma.
Scherrer E; Rau R; Lorenzi M; Shui I; Townson S; Larkin J
Future Oncol; 2021 Jul; 17(20):2683-2692. PubMed ID: 33783230
[No Abstract] [Full Text] [Related]
35. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
[TBL] [Abstract][Full Text] [Related]
36. Quantitative spatial evaluation of tumor-immune interactions in the immunotherapy setting of metastatic melanoma lymph nodes.
Maus RLG; Leontovich AA; Moore RM; Fogarty Z; Guo R; Davidson TM; Tekin B; Atherton C; Schimke JM; Dicke BA; Chen BJ; Markovic SN
Front Immunol; 2022; 13():1024039. PubMed ID: 36544759
[TBL] [Abstract][Full Text] [Related]
37. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
[TBL] [Abstract][Full Text] [Related]
38. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort.
Bai X; Kim M; Kasumova G; Si L; Tang B; Cui C; Yang X; Wei X; Cohen J; Lawrence D; Freedman C; Fadden R; Rubin K; Sharova T; Frederick D; Flaherty K; Sullivan R; Guo J; Boland G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632901
[TBL] [Abstract][Full Text] [Related]
39. MATISSE: a method for improved single cell segmentation in imaging mass cytometry.
Baars MJD; Sinha N; Amini M; Pieterman-Bos A; van Dam S; Ganpat MMP; Laclé MM; Oldenburg B; Vercoulen Y
BMC Biol; 2021 May; 19(1):99. PubMed ID: 33975602
[TBL] [Abstract][Full Text] [Related]
40. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
Restifo NP; Marincola FM; Kawakami Y; Taubenberger J; Yannelli JR; Rosenberg SA
J Natl Cancer Inst; 1996 Jan; 88(2):100-8. PubMed ID: 8537970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
